Taysha Gene Therapies, Inc.
NASDAQ:TSHA
1.63 (USD) • At close November 11, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 15.451 | 2.502 | 0 | 0 | 0 |
| Cost of Revenue
| 1.371 | 2.487 | 0.492 | 0.009 | 0 |
| Gross Profit
| 14.08 | 0.015 | -0.492 | -0.009 | 0 |
| Gross Profit Ratio
| 0.911 | 0.006 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 56.778 | 91.169 | 131.943 | 31.893 | 0.987 |
| General & Administrative Expenses
| 30.047 | 37.36 | 41.324 | 11.109 | 0.512 |
| Selling & Marketing Expenses
| -1.371 | 0 | 0 | 0 | -0.384 |
| SG&A
| 28.676 | 37.36 | 41.324 | 11.109 | 0.128 |
| Other Expenses
| -1.585 | -0.018 | 0 | -17.03 | 0 |
| Operating Expenses
| 85.454 | 128.529 | 173.267 | 43.002 | 1.115 |
| Operating Income
| -71.374 | -162.447 | -173.267 | -43.002 | -1.115 |
| Operating Income Ratio
| -4.619 | -64.927 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -40.192 | -3.567 | -1.256 | -17.009 | 0 |
| Income Before Tax
| -111.566 | -166.014 | -174.523 | -60.011 | -1.115 |
| Income Before Tax Ratio
| -7.221 | -66.353 | 0 | 0 | 0 |
| Income Tax Expense
| 1.203 | 3.567 | 0.936 | -17.011 | -4.46 |
| Net Income
| -111.566 | -169.581 | -175.459 | -43 | -1.115 |
| Net Income Ratio
| -7.221 | -67.778 | 0 | 0 | 0 |
| EPS
| -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted
| -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EBITDA
| -70.003 | -125.796 | -173.095 | -59.983 | -1.115 |
| EBITDA Ratio
| -4.531 | -50.278 | 0 | 0 | 0 |